updat model headwind assum result
includ sale declin medic devic unit due wide spread elect
procedur shutdown pharma consum unit fare better
crisi temper previou growth assumpt remain insul
vs peer coverag univers immun
impact devic dampen outlook rel better
posit insul pharma consum
updat estim recogn revis
best guess junctur ultim unlik accur sale
guidanc last issu vs current street estimate
midpoint reflect adj oper growth impli acceler
level mani compani med-tech alreadi pull guidanc
could potenti follow suit regard financi impact
declin offer estim cite imposs exercis cfo indic
compani base initi project result geograph path
viru respect busi medic devic unit particular weight
toward elect surgeri pharma consum unit bit insul
use public comment compani file deriv revenu estim
medic devic unit geographi look total sale geograph mix us
sale europ sale hemispher ex us sale asiapac africa
sale medic devic geograph mix us ou made assumpt
around quarterli impact level elect procedur declin
exercis arriv hit devic sale estim hit
total sale estim well hit total sale estim meanwhil
consum face easiest comp year attribut
broad market soft pharma unit immun
eg pharma sale oncolog patient delay treatment
reacceler could still play make path bit murkier
would anticip primari driver unit darzalex imbruvica tremfya stelara
erleada penetr indic increas
oper expens estim also challeng project base current
inform think manag tri posit compani come
end crisi posit strength therefor assum
invest sale market modestli temper turn
ep estim ep estim
estim vs consensu medic devic anticip unit bear
brunt impact sale vs street
project pharma expect sale vs street lastli
consum expect mostli in-lin sale number vs consensu
potenti vaccin develop addit select lead
candid vaccin could avail via emerg use
author eua acceler timelin trial later
expand barda partnership co-fund vaccin clinic test
pleas see page report import disclosur
improv fundament combin pharma md consum franchis
continu drive core revenue/ep growth acceler ex fx/olysio headwind
normal period sustain mid-singl digit top-lin organ growth driven pharma
industri lead perform improv medic devic consum
pharma cc revenu growth
blockbust asset continu
bolster strong pipelin
medic devic see declin near
term start
consum acceler lsd growth
report ep growth
growth peer
medic devic reacceler
consum return msd growth
deeper impact remicad biosimilar
medic devic return
competit market growth rate
impact greater expect
pharma pipelin fail deliv near-term
growth opportun off-set remicad
consum margin growth
johnson johnson one world largest diversifi health care compani
offer product world-wide three major busi divis pharma medic
devic diagnost consum product one four compani
aaa credit rate give tremend amount flexibl debt instrument
provid compani unparallel buy sell opportun market
environ consist oper compani locat countri
top three prioriti sharehold dividend judici a/l across
three divis share repurchas elimin dilut compani intend
maintain industry-lead dividend pay-out ratio level higher
compani report thomson eikon cowen compani
year end decemb end decemb end decemb revenu good gross amort interest interest net interest incom incom incom tax incom tax incom restructur non-recur gain incom gaap net incom incl ep incl amort restructur non-recur charg dilut share margin analysisgross analysistot cowen
compani report thomson eikon cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
drug patent expir pharma pipelin price procedur volum risk
med devic failur bring consum product back market follow product
withdraw impact busi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
